Raffaella Bonecchi

List of Publications by Year in Descending Order

70 papers	5,972 citations	32 h-index	74 g-index
74 ext. papers	6,825 ext. citations	7.7 avg, IF	5.54 L-index

#	Paper	IF	Citations
70	Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes.. *Neuro-Oncology Advances*, **2021**, 3, vdab160	0.9	0
69	Multiple Roles for Chemokines in Neutrophil Biology. *Frontiers in Immunology*, **2020**, 11, 1259	8.4	40
68	Neutrophil diversity and plasticity in tumour progression and therapy. *Nature Reviews Cancer*, **2020**, 20, 485-503	31.3	178
67	Control of Cytoskeletal Dynamics by β-Arrestin1/Myosin Vb Signaling Regulates Endosomal Sorting and Scavenging Activity of the Atypical Chemokine Receptor ACKR2. *Vaccines*, **2020**, 8,	5.3	1
66	Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy. *Frontiers in Immunology*, **2019**, 10, 379	8.4	201
65	ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity. *Nature Communications*, **2018**, 9, 676	17.4	40
64	Regulation of hematopoiesis by the chemokine system. *Cytokine*, **2018**, 109, 76-80	4	10
63	Chemokines sound the alarmin: The role of atypical chemokine in inflammation and cancer. *Seminars in Immunology*, **2018**, 38, 63-71	10.7	21
62	Atypical matters in myeloid differentiation. *Nature Immunology*, **2017**, 18, 711-712	19.1	3
61	Neutrophils in Gliomas. *Frontiers in Immunology*, **2017**, 8, 1349	8.4	59
60	Atypical Chemokine Receptors **2016**, 579-585		
59	Flow Cytometry Detection of Chemokine Receptors for the Identification of Murine Monocyte and Neutrophil Subsets. *Methods in Enzymology*, **2016**, 570, 441-56	1.7	1
58	Atypical chemokine receptors in cancer: friends or foes?. *Journal of Leukocyte Biology*, **2016**, 99, 927-33	6.5	54
57	ACKR2: An Atypical Chemokine Receptor Regulating Lymphatic Biology. *Frontiers in Immunology*, **2016**, 7, 691	8.4	11
56	CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis. *PLoS ONE*, **2016**, 11, e0166006	3.7	20
55	Atypical Chemokine Receptors and Their Roles in the Resolution of the Inflammatory Response. *Frontiers in Immunology*, **2016**, 7, 224	8.4	82
54	Cancer and Chemokines. *Methods in Molecular Biology*, **2016**, 1393, 87-96	1.4	16

53	Chemokine regulation of neutrophil function in tumors. *Cytokine and Growth Factor Reviews*, **2016**, 30, 81-6	17.9	18
52	Colonic Macrophages "Remote Control" Adipose Tissue Inflammation and Insulin Resistance. *Cell Metabolism*, **2016**, 24, 196-8	24.6	2
51	Cytokine decoy and scavenger receptors as key regulators of immunity and inflammation. *Cytokine*, **2016**, 87, 37-45	4	26
50	Myeloid cells in cancer-related inflammation. *Immunobiology*, **2015**, 220, 249-53	3.4	50
49	Chemokines as effector and target molecules in vascular biology. *Cardiovascular Research*, **2015**, 107, 364-72	9.9	23
48	Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness. *OncoImmunology*, **2014**, 3, e955337	7.2	4
47	Flow cytometry applications for the analysis of chemokine receptor expression and function. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2014**, 85, 292-301	4.6	10
46	ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma. *Cancer Immunology Research*, **2014**, 2, 679-89	12.5	27
45	Review: Structure-function and biological properties of the atypical chemokine receptor D6. *Molecular Immunology*, **2013**, 55, 87-93	4.3	7
44	Dissecting trafficking and signaling of atypical chemokine receptors. *Methods in Enzymology*, **2013**, 521, 151-68	1.7	2
43	Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. *International Journal of Cancer*, **2013**, 133, 383-93	7.5	16
42	β-arrestin-dependent activation of the cofilin pathway is required for the scavenging activity of the atypical chemokine receptor D6. *Science Signaling*, **2013**, 6, ra30.1-11, S1-3	8.8	44
41	Atypical chemokine receptors: from silence to sound. *Biochemical Society Transactions*, **2013**, 41, 231-6	5.1	23
40	CCRL2, a fringe member of the atypical chemoattractant receptor family. *European Journal of Immunology*, **2013**, 43, 1418-22	6.1	28
39	Expression of the atypical chemokine receptor D6 in human alveolar macrophages in COPD. *Chest*, **2013**, 143, 98-106	5.3	32
38	Control of murine Ly6C(high) monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6. *Blood*, **2012**, 119, 5250-60	2.2	28
37	The chemokine decoy receptor D6 prevents excessive inflammation and adverse ventricular remodeling after myocardial infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 2206-13	9.4	64
36	Targeting Chemokines in Cancer. *Current Immunology Reviews*, **2012**, 8, 161-169	1.3	1

35	Chemokines and cancer: a fatal attraction. *Cancer Cell*, **2011**, 19, 434-5	24.3	64
34	Chemokine decoy receptors: structure-function and biological properties. *Current Topics in Microbiology and Immunology*, **2010**, 341, 15-36	3.3	38
33	The chemokine system in cancer biology and therapy. *Cytokine and Growth Factor Reviews*, **2010**, 21, 27-39	17.9	298
32	The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. *Gut*, **2010**, 59, 197-206	19.2	123
31	Chemokine receptors intracellular trafficking. *Pharmacology & Therapeutics*, **2010**, 127, 1-8	13.9	70
30	Chemokines and chemokine receptors: an overview. *Frontiers in Bioscience - Landmark*, **2009**, 14, 540-51	2.8	181
29	Recognition versus adaptive up-regulation and degradation of CC chemokines by the chemokine decoy receptor D6 are determined by their N-terminal sequence. *Journal of Biological Chemistry*, **2009**, 284, 26207-15	5.4	43
28	Shaping the gradient by nonchemotactic chemokine receptors. *Cell Adhesion and Migration*, **2009**, 3, 146-52	3.2	5
27	Role of the chemokine scavenger receptor D6 in balancing inflammation and immune activation. *Methods in Enzymology*, **2009**, 460, 231-43	1.7	9
26	Chemoattractant receptors and leukocyte recruitment: more than cell migration. *Science Signaling*, **2009**, 2, pe10	8.8	3
25	Non-signaling chemokine receptors: mechanism of action and role in vivo. *Journal of Neuroimmunology*, **2008**, 198, 14-9	3.5	7
24	Chemokine decoy receptors: new players in reproductive immunology. *Immunological Investigations* , **2008**, 37, 483-97	2.9	30
23	Transmigration at the borders: Recycling and trafficking of adhesion molecules. *Cell Adhesion and Migration*, **2008**, 2, 55-6	3.2	2
22	Regulation of D6 chemokine scavenging activity by ligand- and Rab11-dependent surface up-regulation. *Blood*, **2008**, 112, 493-503	2.2	67
21	Chemokines as pharmacological targets. *Mini-Reviews in Medicinal Chemistry*, **2008**, 8, 638-46	3.2	11
20	Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 2319-24	11.5	150
19	Cytokines in Liver Health and Disease **2007**, 83-93		1
18	D6 as a Decoy and Scavenger Receptor for Inflammatory CC Chemokines in the Skin. *Handbook of Systemic Autoimmune Diseases*, **2006**, 23-28	0.3	1

17	The chemoattractant decoy receptor D6 as a negative regulator of inflammatory responses. *Biochemical Society Transactions*, **2006**, 34, 1014-7	5.1	11
16	Tuning inflammation and immunity by chemokine sequestration: decoys and more. *Nature Reviews Immunology*, **2006**, 6, 907-18	36.5	382
15	Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. *Cytokine and Growth Factor Reviews*, **2005**, 16, 679-86	17.9	87
14	Increased inflammation in mice deficient for the chemokine decoy receptor D6. *European Journal of Immunology*, **2005**, 35, 1342-6	6.1	119
13	Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. *Journal of Immunology*, **2004**, 172, 4972-6	5.3	117
12	beta-Arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6. *Journal of Biological Chemistry*, **2004**, 279, 25590-7	5.4	125
11	Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. *Journal of Pathology*, **2003**, 200, 255-68	9.4	240
10	Tuning of innate immunity and polarized responses by decoy receptors. *International Archives of Allergy and Immunology*, **2003**, 132, 109-15	3.7	26
9	Unique regulation of CCL18 production by maturing dendritic cells. *Journal of Immunology*, **2003**, 170, 3843-9	5.3	134
8	Selective induction of phospholipase D1 in pathogen-activated human monocytes. *Biochemical Journal*, **2001**, 358, 119-25	3.8	11
7	Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. *European Journal of Immunology*, **2001**, 31, 812-22	6.1	218
6	Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. *Journal of Immunology*, **2000**, 164, 3862-9	5.3	109
5	Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. *Journal of Leukocyte Biology*, **1999**, 66, 489-94	6.5	124
4	Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. *Journal of Experimental Medicine*, **1998**, 187, 129-34	16.6	1793
3	Divergent Effects of Interleukin-4 and Interferon-□bn Macrophage-Derived Chemokine Production: An Amplification Circuit of Polarized T Helper 2 Responses. *Blood*, **1998**, 92, 2668-2671	2.2	175
2	Divergent Effects of Interleukin-4 and Interferon-□bn Macrophage-Derived Chemokine Production: An Amplification Circuit of Polarized T Helper 2 Responses. *Blood*, **1998**, 92, 2668-2671	2.2	4
1	Human monocyte-derived and CD34+ cell-derived dendritic cells express functional receptors for platelet activating factor. *FEBS Letters*, **1997**, 418, 98-100	3.8	42